A recent report ongoing study by Infinium Global Research on the AI-based clinical trials solution provider market provides an in-depth analysis of segments and sub-segments in the MENA as well as regional AI-based clinical trials solution provider market. The study also highlights the impact of drivers, restraints, and macro indicators on the MENA and regional AI-based clinical trials solution provider market over the short term as well as long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of the MENA AI-based clinical trials solution provider market. According to the report, the MENA AI-based clinical trials solution provider market is projected to grow at a significant CAGR over the forecast period of 2022-2028.
Artificial intelligence and machine learning technologies are showing incredible potential in improving clinical research and development productivity.AI has many potential applications in clinical trials both near- and long-term. AI technologies make possible innovations that are fundamental for transforming clinical trials, such as seamlessly combining phases I and II of clinical trials, developing novel patient-centered endpoints, and collecting and analyzing Real-World Data. An array of services has emerged in modern therapy development that offers AI capabilities in designing and managing the operation of clinical studies. The machine learning-based advanced analytics show a vast potential in impacting the entire continuum of a clinical trial, ranging from target identification to patient recruitment to analyzing results of studies.
The sudden outbreak of the Covid-19 pandemic has initiated an augmentation in the deployment of AI-sourced technologies. The rising acceptance of scientifically highly developed results, intended for the drug invention, improvement along with the scrutiny of enlisted information of the patients is a few factors, accountable for the rise in the infiltration of AI-sourced medicine development as well as clinical trial results, throughout the Covid-19 pandemic. As the pandemic caused numerous clinical trials kept on hold, key companies moved in the direction of accessible information of the patients, in that way increasing decentralized clinical trials. This has encouraged AI-sourced solution suppliers because of the efficiency of their tools in information consolidation and analysis.
The shifting trend from traditional practices of drug development to a technology-based approach by major pharmaceutical companies is also driving the market growth. Moreover, the positive attitude of key market players towards the utilization of AI-based technologies in clinical trials and overall drug discovery and development is likely to boost market growth during the forecast period. Stringent regulations associated with approval of AI-based clinical trials and lack of AI accuracy in clinical practice due to insufficient availability of data is a key hinder AI-based clinical trials solution provider market. Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors will provide lucrative growth for their market growth.
UAE dominates the AI-based clinical trials solution provider market. The largest healthcare network in the United Arab Emirates. With the increasing incidence of chronic diseases, cancer, and hematological disorders that require life-saving drugs, the MENA region needs a sustainable and robust clinical research infrastructure. The UAE has an immense capacity for research and the substrate to develop a strong regulatory framework, which makes it an ideal location to build a CRO to service the needs of the region. With its surrounding population size and diversity in genetic profile and lifestyle, IROS has the perfect landscape to foster research and testing, leading to innovative new drugs and therapies.
The report on MENA AI-based clinical trials solution provider market covers segments such as the clinical trial phase and therapeutic application. On the basis of the clinical trial phase, the sub-markets include Phase-I, Phase-II, and Phase-III. On the basis of therapeutic application, the sub-markets include cancer, cardiovascular disease, neurological disease, metabolic disease, infectious disease, and others.
The report provides profiles of the companies in the market such as Unlearn AI Inc, Saama Technologies, Inc, Deep 6 AI, Innoplexus, Symphony AI, Mendel.ai, AiCure, and Ardigen, BioSymetrics, and GNS Healthcare.
The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors driving and restraining this market's growth. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the MENA AI-based clinical trials solution provider market. Moreover, the study highlights current market trends and provides forecasts for 2022-2028. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.
Please Choose One of them.